<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527488</url>
  </required_header>
  <id_info>
    <org_study_id>FE200486 CS25</org_study_id>
    <secondary_id>2007-003578-24</secondary_id>
    <nct_id>NCT00527488</nct_id>
  </id_info>
  <brief_title>Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.</brief_title>
  <official_title>A Single-centre, Open-label, Randomised Explorative Pharmacokinetic/Pharmacodynamic Study of the Gonadotropin-releasing Hormone Receptor Antagonist Degarelix (FE 200486) in Patients With Benign Prostatic Hyperplasia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory study will be conducted open label in a single investigational clinical
      unit. Altogether 52 patients with benign prostate hyperplasia (BPH) will be randomly assigned
      to receive 4 different treatments with degarelix.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study aims at exploring the potential of the currently available formulation of
      degarelix to treat BPH with only a short transient lowering of the serum testosterone
      concentration to or below the castration level defined as 0.5 ng/mL. Two doses and two dosing
      regimens (32 and 64 mg administered either as a single administration or as two
      administrations separated by 14 days) will be evaluated for 42 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Testosterone Area Below Baseline Interval</measure>
    <time_frame>0-42 Days</time_frame>
    <description>The area of the testosterone concentration (ng/mL) vs. time (days) curve that is below the baseline interval concentration( i.e. 0.75 x baseline concentration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Testosterone Concentration Below Baseline Interval</measure>
    <time_frame>Day 0-42</time_frame>
    <description>The time from when the testosterone concentration falls below the baseline interval limit (i.e. 0.75 x baseline concentration) until it returns above this limit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal Value of Testosterone (Cnadir)</measure>
    <time_frame>Day 0-42</time_frame>
    <description>The lowest concentration of testosterone measured within the time frame</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Minimal Value of Testosterone (Tnadir)</measure>
    <time_frame>Day 0-42</time_frame>
    <description>The time point when the lowest testosterone concentration was measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Testosterone Concentration Below 0.5 ng/mL</measure>
    <time_frame>Day 0-42</time_frame>
    <description>The time from when the testosterone concentration falls below 0.5 ng/mL until it returns above that level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Testosterone Concentration â‰¤0.5 ng/mL</measure>
    <time_frame>Day 0-42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Testosterone Concentration at or Above the Baseline Interval Concentration</measure>
    <time_frame>Day 0-42</time_frame>
    <description>The baseline interval concentration is 0.75 x baseline concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostate Specific Antigen (PSA) Concentration</measure>
    <time_frame>Day 0-42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostate Volume</measure>
    <time_frame>Day 0-42</time_frame>
    <description>The prostatic volume was measured by transrectal ultrasound. The prostatic gland was sonicated from two directions perpendicular to one another resulting in three cursor positions set by the urologist, and the volume automatically calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal Urinary Flow</measure>
    <time_frame>Day 0-42</time_frame>
    <description>Urinary flow was determined by flowmetry using a device that fulfils the International Continence Society standards for maximum urinary flow.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-void Residual Urine Volume</measure>
    <time_frame>Day 0-42</time_frame>
    <description>The post-void residual urine volume in the bladder was evaluated by transabdominal ultrasound. The urine bladder was sonicated from two directions perpendicular to one another, and the volume calculated automatically.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>International Prostate Specific Symptom (IPSS) Score</measure>
    <time_frame>Day 0-42</time_frame>
    <description>The IPSS is a patient-administered questionnaire containing seven items to evaluate symptoms of urinary obstruction (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, nocturia) over the preceding week. Each urinary symptom question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The total score can therefore range from 0 to 35 (0-7: mildly symptomatic; 8-19: moderately symptomatic; 20-35: severely symptomatic).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IPSS Global Quality of Life</measure>
    <time_frame>Day 0-42</time_frame>
    <description>Patients were asked about how they would feel if they were to spend the rest of their lives with their prostate symptoms just as they are now. The answers choices range from &quot;delighted&quot; to &quot;terrible&quot; or 0 to 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interntional Iindes of Erectile Function (IIEF) Score: Overall Satisfaction</measure>
    <time_frame>Day 0-42</time_frame>
    <description>The IIEF contains 15 items in 5 domains: Erectile Function (6 items), Orgasmic Function (2 items), Sexual Desire (2 items), Intercourse Satisfaction (3 items), and Overall Satisfaction (2 items). Item are scored on a scale from 'No sexual activity' to 'Almost always to always'. For the Erectile Function domain, a score of 1-10 indicates severe erectile dysfunction and 26-30 no dysfunction, the minimum score being 1 and the maximum 30. For all other domains, a higher score indicates less dysfunction. The IIEF does not yield a total score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters of Degarelix: AUCt</measure>
    <time_frame>0-42 Days</time_frame>
    <description>Area under the time-concentration curve (AUCt) was calculated by non-compartmental methods based on data up to Day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters of Degarelix: Cmax</measure>
    <time_frame>Day 0-42</time_frame>
    <description>Cmax was determined for concentration measurements up to Day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters of Degarelix: Tmax</measure>
    <time_frame>Day 0-42</time_frame>
    <description>The time for maximal concentration (tmax) was determined for data up to Day 42</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>BPH</condition>
  <arm_group>
    <arm_group_label>Degarelix 16+16 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 32 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 32+32 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 64 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.</description>
    <arm_group_label>Degarelix 16+16 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>One dose of 32 mg administered as a single administration will be evaluated for 42 days.</description>
    <arm_group_label>Degarelix 32 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.</description>
    <arm_group_label>Degarelix 32+32 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>One dose of 64 mg administered as a single administration will be evaluated for 42 days.</description>
    <arm_group_label>Degarelix 64 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each patient must comply with all of the following inclusion criteria to be allowed to be
        randomised into the study:

          1. Man, 55 to 75 years of age.

          2. Clinical diagnose of BPH with a prostate volume more than 30 mL, a maximal uroflow of
             12 mL/sec or less and an international prostate sympton score (IPSS) of 13 or more at
             screening.

          3. A prostate specific antigen (PSA) value less than 10 ng/mL and no clinical evidence of
             adenocarcinoma of the prostate at screening. If a biopsy of the prostate is performed,
             a period of 6 weeks should be allowed after the biopsy before the patient is enrolled
             into the study.

          4. Has a baseline testosterone level above 3 ng/mL at screening.

        Exclusion Criteria:

        Any patient meeting one or more of the following exclusion criteria will not be included
        into the study:

          1. Previous surgery of the prostate.

          2. Previous treatment with GnRH agonists or GnRH antagonists.

          3. Treatment with 5-alpha reductase inhibitors, e.g., finasteride (ProscaÂ®)or dutasteride
             (AvodartÂ®) within the past 12 months before the study.

          4. Treatment with alpha-adrenergic antagonists, e.g., terazosin, doxazosin, tamsulosin,
             alfuzosin within 2 weeks prior to Screening part II (or Part I, if IPSS is performed
             at Screening part I).

          5. Treatment with any drug modifying the testosterone level or function within 12 weeks
             before Screening visit part II (or Part I, if IPSS is performed at Screening part I).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRS Clinical Research Services Monchengladback GmbH</name>
      <address>
        <city>Monchengladbach</city>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2007</study_first_submitted>
  <study_first_submitted_qc>September 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2007</study_first_posted>
  <results_first_submitted>August 16, 2010</results_first_submitted>
  <results_first_submitted_qc>October 27, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2010</results_first_posted>
  <disposition_first_submitted>April 9, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>April 9, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 12, 2010</disposition_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benign Prostate Hyperplasia</keyword>
  <keyword>BPH</keyword>
  <keyword>PK/PD</keyword>
  <keyword>GnRH antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Degarelix 16+16 mg</title>
          <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
        </group>
        <group group_id="P2">
          <title>Degarelix 32 mg</title>
          <description>A single dose of Degarelix 32 mg on Day 0</description>
        </group>
        <group group_id="P3">
          <title>Degarelix 32+32 mg</title>
          <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
        </group>
        <group group_id="P4">
          <title>Degarelix 64 mg</title>
          <description>A single dose of Degarelix 64 mg on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawn prior to dosing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Degarelix 16+16 mg</title>
          <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
        </group>
        <group group_id="B2">
          <title>Degarelix 32 mg</title>
          <description>A single dose of Degarelix 32 mg on Day 0</description>
        </group>
        <group group_id="B3">
          <title>Degarelix 32+32 mg</title>
          <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
        </group>
        <group group_id="B4">
          <title>Degarelix 64 mg</title>
          <description>A single dose of Degarelix 64 mg on Day 0</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.7" spread="4.7"/>
                    <measurement group_id="B2" value="63.0" spread="6.1"/>
                    <measurement group_id="B3" value="66.3" spread="4.6"/>
                    <measurement group_id="B4" value="60.4" spread="7.8"/>
                    <measurement group_id="B5" value="63.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Testosterone Area Below Baseline Interval</title>
        <description>The area of the testosterone concentration (ng/mL) vs. time (days) curve that is below the baseline interval concentration( i.e. 0.75 x baseline concentration)</description>
        <time_frame>0-42 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Testosterone Area Below Baseline Interval</title>
          <description>The area of the testosterone concentration (ng/mL) vs. time (days) curve that is below the baseline interval concentration( i.e. 0.75 x baseline concentration)</description>
          <units>ng*days/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" spread="19.1"/>
                    <measurement group_id="O2" value="16.0" spread="11.6"/>
                    <measurement group_id="O3" value="54.6" spread="25.7"/>
                    <measurement group_id="O4" value="70.6" spread="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters of Degarelix: AUCt</title>
        <description>Area under the time-concentration curve (AUCt) was calculated by non-compartmental methods based on data up to Day 42</description>
        <time_frame>0-42 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of Degarelix: AUCt</title>
          <description>Area under the time-concentration curve (AUCt) was calculated by non-compartmental methods based on data up to Day 42</description>
          <units>ng*day/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" spread="20.6"/>
                    <measurement group_id="O2" value="86.9" spread="26.9"/>
                    <measurement group_id="O3" value="158" spread="43.7"/>
                    <measurement group_id="O4" value="176" spread="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Testosterone Concentration Below Baseline Interval</title>
        <description>The time from when the testosterone concentration falls below the baseline interval limit (i.e. 0.75 x baseline concentration) until it returns above this limit</description>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Testosterone Concentration Below Baseline Interval</title>
          <description>The time from when the testosterone concentration falls below the baseline interval limit (i.e. 0.75 x baseline concentration) until it returns above this limit</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="12.8"/>
                    <measurement group_id="O2" value="13.2" spread="9.3"/>
                    <measurement group_id="O3" value="34.3" spread="10.8"/>
                    <measurement group_id="O4" value="34.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimal Value of Testosterone (Cnadir)</title>
        <description>The lowest concentration of testosterone measured within the time frame</description>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Value of Testosterone (Cnadir)</title>
          <description>The lowest concentration of testosterone measured within the time frame</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.5"/>
                    <measurement group_id="O2" value="0.9" spread="0.5"/>
                    <measurement group_id="O3" value="0.4" spread="0.3"/>
                    <measurement group_id="O4" value="0.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Minimal Value of Testosterone (Tnadir)</title>
        <description>The time point when the lowest testosterone concentration was measured</description>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Minimal Value of Testosterone (Tnadir)</title>
          <description>The time point when the lowest testosterone concentration was measured</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.6"/>
                    <measurement group_id="O2" value="1.3" spread="0.8"/>
                    <measurement group_id="O3" value="4.3" spread="5.3"/>
                    <measurement group_id="O4" value="8.8" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Testosterone Concentration Below 0.5 ng/mL</title>
        <description>The time from when the testosterone concentration falls below 0.5 ng/mL until it returns above that level</description>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Testosterone Concentration Below 0.5 ng/mL</title>
          <description>The time from when the testosterone concentration falls below 0.5 ng/mL until it returns above that level</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.0" upper_limit="41.1"/>
                    <measurement group_id="O4" value="2.0" lower_limit="0.0" upper_limit="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Testosterone Concentration â‰¤0.5 ng/mL</title>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Testosterone Concentration â‰¤0.5 ng/mL</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Testosterone Concentration at or Above the Baseline Interval Concentration</title>
        <description>The baseline interval concentration is 0.75 x baseline concentration</description>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Testosterone Concentration at or Above the Baseline Interval Concentration</title>
          <description>The baseline interval concentration is 0.75 x baseline concentration</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prostate Specific Antigen (PSA) Concentration</title>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Specific Antigen (PSA) Concentration</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="3.2"/>
                    <measurement group_id="O2" value="3.0" spread="2.6"/>
                    <measurement group_id="O3" value="2.8" spread="2.5"/>
                    <measurement group_id="O4" value="3.2" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.5"/>
                    <measurement group_id="O2" value="2.5" spread="1.7"/>
                    <measurement group_id="O3" value="2.4" spread="2.6"/>
                    <measurement group_id="O4" value="2.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prostate Volume</title>
        <description>The prostatic volume was measured by transrectal ultrasound. The prostatic gland was sonicated from two directions perpendicular to one another resulting in three cursor positions set by the urologist, and the volume automatically calculated.</description>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Volume</title>
          <description>The prostatic volume was measured by transrectal ultrasound. The prostatic gland was sonicated from two directions perpendicular to one another resulting in three cursor positions set by the urologist, and the volume automatically calculated.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" spread="12.1"/>
                    <measurement group_id="O2" value="48.7" spread="21.0"/>
                    <measurement group_id="O3" value="38.1" spread="7.1"/>
                    <measurement group_id="O4" value="38.9" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" spread="11.0"/>
                    <measurement group_id="O2" value="34.8" spread="14.2"/>
                    <measurement group_id="O3" value="28.7" spread="8.2"/>
                    <measurement group_id="O4" value="30.6" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximal Urinary Flow</title>
        <description>Urinary flow was determined by flowmetry using a device that fulfils the International Continence Society standards for maximum urinary flow.</description>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Urinary Flow</title>
          <description>Urinary flow was determined by flowmetry using a device that fulfils the International Continence Society standards for maximum urinary flow.</description>
          <units>mL/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="4.7"/>
                    <measurement group_id="O2" value="11.7" spread="3.4"/>
                    <measurement group_id="O3" value="9.7" spread="4.1"/>
                    <measurement group_id="O4" value="9.1" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="4.3"/>
                    <measurement group_id="O2" value="11.2" spread="4.0"/>
                    <measurement group_id="O3" value="12.2" spread="9.3"/>
                    <measurement group_id="O4" value="11.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Post-void Residual Urine Volume</title>
        <description>The post-void residual urine volume in the bladder was evaluated by transabdominal ultrasound. The urine bladder was sonicated from two directions perpendicular to one another, and the volume calculated automatically.</description>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Post-void Residual Urine Volume</title>
          <description>The post-void residual urine volume in the bladder was evaluated by transabdominal ultrasound. The urine bladder was sonicated from two directions perpendicular to one another, and the volume calculated automatically.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4" lower_limit="4.8" upper_limit="170"/>
                    <measurement group_id="O2" value="60.7" lower_limit="0.0" upper_limit="157"/>
                    <measurement group_id="O3" value="56.7" lower_limit="8.4" upper_limit="201"/>
                    <measurement group_id="O4" value="91.3" lower_limit="4.6" upper_limit="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0" lower_limit="0.3" upper_limit="215"/>
                    <measurement group_id="O2" value="45.2" lower_limit="0.0" upper_limit="108"/>
                    <measurement group_id="O3" value="34.6" lower_limit="0.0" upper_limit="165"/>
                    <measurement group_id="O4" value="75.8" lower_limit="0.0" upper_limit="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>International Prostate Specific Symptom (IPSS) Score</title>
        <description>The IPSS is a patient-administered questionnaire containing seven items to evaluate symptoms of urinary obstruction (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, nocturia) over the preceding week. Each urinary symptom question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The total score can therefore range from 0 to 35 (0-7: mildly symptomatic; 8-19: moderately symptomatic; 20-35: severely symptomatic).</description>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>International Prostate Specific Symptom (IPSS) Score</title>
          <description>The IPSS is a patient-administered questionnaire containing seven items to evaluate symptoms of urinary obstruction (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, nocturia) over the preceding week. Each urinary symptom question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The total score can therefore range from 0 to 35 (0-7: mildly symptomatic; 8-19: moderately symptomatic; 20-35: severely symptomatic).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="4.5"/>
                    <measurement group_id="O2" value="22.3" spread="6.5"/>
                    <measurement group_id="O3" value="18.2" spread="5.4"/>
                    <measurement group_id="O4" value="21.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="4.5"/>
                    <measurement group_id="O2" value="9.1" spread="6.2"/>
                    <measurement group_id="O3" value="8.6" spread="5.7"/>
                    <measurement group_id="O4" value="11.8" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IPSS Global Quality of Life</title>
        <description>Patients were asked about how they would feel if they were to spend the rest of their lives with their prostate symptoms just as they are now. The answers choices range from &quot;delighted&quot; to &quot;terrible&quot; or 0 to 6.</description>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>IPSS Global Quality of Life</title>
          <description>Patients were asked about how they would feel if they were to spend the rest of their lives with their prostate symptoms just as they are now. The answers choices range from &quot;delighted&quot; to &quot;terrible&quot; or 0 to 6.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.1"/>
                    <measurement group_id="O2" value="3.8" spread="1.7"/>
                    <measurement group_id="O3" value="4.3" spread="1.3"/>
                    <measurement group_id="O4" value="4.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.4"/>
                    <measurement group_id="O2" value="1.8" spread="2.0"/>
                    <measurement group_id="O3" value="1.9" spread="1.6"/>
                    <measurement group_id="O4" value="2.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interntional Iindes of Erectile Function (IIEF) Score: Overall Satisfaction</title>
        <description>The IIEF contains 15 items in 5 domains: Erectile Function (6 items), Orgasmic Function (2 items), Sexual Desire (2 items), Intercourse Satisfaction (3 items), and Overall Satisfaction (2 items). Item are scored on a scale from â€˜No sexual activityâ€™ to â€˜Almost always to alwaysâ€™. For the Erectile Function domain, a score of 1-10 indicates severe erectile dysfunction and 26-30 no dysfunction, the minimum score being 1 and the maximum 30. For all other domains, a higher score indicates less dysfunction. The IIEF does not yield a total score.</description>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Interntional Iindes of Erectile Function (IIEF) Score: Overall Satisfaction</title>
          <description>The IIEF contains 15 items in 5 domains: Erectile Function (6 items), Orgasmic Function (2 items), Sexual Desire (2 items), Intercourse Satisfaction (3 items), and Overall Satisfaction (2 items). Item are scored on a scale from â€˜No sexual activityâ€™ to â€˜Almost always to alwaysâ€™. For the Erectile Function domain, a score of 1-10 indicates severe erectile dysfunction and 26-30 no dysfunction, the minimum score being 1 and the maximum 30. For all other domains, a higher score indicates less dysfunction. The IIEF does not yield a total score.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="1.8"/>
                    <measurement group_id="O2" value="6.5" spread="2.5"/>
                    <measurement group_id="O3" value="5.8" spread="2.6"/>
                    <measurement group_id="O4" value="5.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="1.8"/>
                    <measurement group_id="O2" value="6.2" spread="3.2"/>
                    <measurement group_id="O3" value="6.0" spread="3.0"/>
                    <measurement group_id="O4" value="5.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters of Degarelix: Cmax</title>
        <description>Cmax was determined for concentration measurements up to Day 42</description>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of Degarelix: Cmax</title>
          <description>Cmax was determined for concentration measurements up to Day 42</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="1.2"/>
                    <measurement group_id="O2" value="6.9" spread="1.9"/>
                    <measurement group_id="O3" value="9.6" spread="3.0"/>
                    <measurement group_id="O4" value="15.8" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters of Degarelix: Tmax</title>
        <description>The time for maximal concentration (tmax) was determined for data up to Day 42</description>
        <time_frame>Day 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 16+16 mg</title>
            <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 32 mg</title>
            <description>A single dose of Degarelix 32 mg on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 32+32 mg</title>
            <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 64 mg</title>
            <description>A single dose of Degarelix 64 mg on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of Degarelix: Tmax</title>
          <description>The time for maximal concentration (tmax) was determined for data up to Day 42</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.0"/>
                    <measurement group_id="O2" value="1.3" spread="0.8"/>
                    <measurement group_id="O3" value="1.1" spread="0.6"/>
                    <measurement group_id="O4" value="1.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0-42</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Degarelix 16+16 mg</title>
          <description>Two doses of Degarelix 16 mg on Day 0 and Day 14</description>
        </group>
        <group group_id="E2">
          <title>Degarelix 32 mg</title>
          <description>A single dose of Degarelix 32 mg on Day 0</description>
        </group>
        <group group_id="E3">
          <title>Degarelix 32+32 mg</title>
          <description>Two doses of Degarelix 32 mg on Day 0 and Day 14</description>
        </group>
        <group group_id="E4">
          <title>Degarelix 64 mg</title>
          <description>A single dose of Degarelix 64 mg on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <description>Causality to degarelix regarded as unlikely by the investigator</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Causality regarded as unlikely by the investigator</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="29" subjects_affected="11" subjects_at_risk="13"/>
                <counts group_id="E2" events="25" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E3" events="39" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E4" events="37" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of libido</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Libido increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After the end of the study, one or more manuscripts for joint publication may be prepared in collaboration between the investigator(s) offered authorship and Ferring Pharmaceuticals A/S (Ferring). Ferring reserves the right to be last author(s) in all publications related to this study. In the event of any disagreement in the content of any publication, both the Investigatorâ€™s and Ferringâ€™s opinion will be fairly and sufficiently represented in the publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

